Cingulate Inc. Common Stock (CING)

About CING

Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-210…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

14

Website

www.cingulate.com/

Fundamentals

1-day range

$5.26$5.48

Market cap

$65.06M

P/E (trailing)

—

P/E (forward)

-6.05

EPS (trailing)

$-4.33

Dividend yield

—

Beta

-0.88

Avg. volume

367.4K

Forecasts

5 analyst ratings

Cingulate Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• CING

  Cingulate Inc. Common Stock

  $5.32

  ▼ 2.21%
  Market cap $65.06MP/E —
  $3.16$11.89
• MNOV

  Medicinova Inc Common Stock

  $1.44

  ▲ 1.05%
  Market cap $65.46MP/E —
  $1.17$1.96
• PLRX

  Pliant Therapeutics Inc. Common Stock

  $1.11

  ▼ 3.48%
  Market cap $64.40MP/E —
  $1.02$1.95
• ELTX

  Elicio Therapeutics Inc. Common Stock

  $2.86

  ▼ 4.67%
  Market cap $65.84MP/E —
  $2.66$16
• RNTX

  Rein Therapeutics Inc. Common Stock

  $0.7621

  ▼ 2.67%
  Market cap $63.77MP/E —
  $0.694$2.18
• SPRO

  Spero Therapeutics Inc. Common Stock

  $1.2

  ▼ 0.83%
  Market cap $66.59MP/E 4.73
  $1.08$3.08
• ACRV

  Acrivon Therapeutics Inc. Common Stock

  $2.06

  ▼ 4.19%
  Market cap $66.77MP/E —
  $1.27$3.56

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Roth Capital Reiterates Buy on Cingulate, Lowers Price Target to $9
  benzinga · 8/24/2026
• Roth Capital Reiterates Buy on Cingulate, Lowers Price Target to $9
  Benzinga · 8/24/2026
• Ascendiant Capital Maintains Buy on Cingulate, Lowers Price Target to $44
  Benzinga · 8/20/2026
• CING: Second Quarter Results
  Yahoo · 8/19/2026
• Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness
  Yahoo · 8/13/2026
• Cingulate Q2 EPS $(0.45) Beats $(0.63) Estimate
  Benzinga · 8/13/2026
• Cingulate Publishes Peer-Reviewed Data Demonstrating CTx-1301’s Differentiated Pharmacokinetic Profile
  Yahoo · 8/11/2026

• Shane J. Schaffer · July 16, 2026 · Grant

  97.3K
• Shane J. Schaffer · July 16, 2026 · Grant

  197.7K
• Downey Bryan Wade · July 16, 2026 · Grant

  33.0K
• Downey Bryan Wade · July 16, 2026 · Grant

  67.0K
• Lawrence Bryan Jay · July 16, 2026 · Grant

  20.0K
• Matthew Brams · July 16, 2026 · Grant

  26.4K
• Matthew Brams · July 16, 2026 · Grant

  53.6K
• Thomas Jeffrey Hargroves · July 16, 2026 · Grant

  20.0K
• Jennifer L. Callahan · July 16, 2026 · Grant

  19.8K
• Jennifer L. Callahan · July 16, 2026 · Grant

  40.2K
• Peter J. Werth · July 16, 2026 · Grant

  20.0K
• Raul R. Silva · July 16, 2026 · Grant

  26.4K
• Raul R. Silva · July 16, 2026 · Grant

  53.6K
• Raul R. Silva · June 30, 2026 · Grant

  3.9K
• Raul R. Silva · March 31, 2026 · Grant

  3.4K

Institutional Ownership

March 31, 2026

Total shares held

1.13M

Total value held

$6.65M

Institutional holders

25